Intellia Therapeutics price target lowered to $48 from $60 at Chardan

Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps a Buy rating on the shares. Intellia Therapeutics paused dosing and screening in its MAGNITUDE trials of nexiguran ziclumeran for ATTR after a patient developed severe liver enzyme and bilirubin elevations meeting Hy’s law criteria, the analyst tells investors in a research note. The incident, now under review, is expected to delay the program by about one quarter and may dampen confidence in nex-z’s safety profile relative to other ATTR treatments until clearer mitigation measures emerge, the firm says.